Related Experiment Video

Updated: May 23, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Oncogramme responses of breast tumour cells treated with herceptin correlate with HER2/C-ERB B2 pathological status

S Giraud1, C Bounaix Morand du Puch, V Fermeaux

  • 1Oncomedics, ESTER Technopole, Limoges, France. s.giraud@oncomedics.com

Anticancer Research
|April 12, 2012
PubMed
Abstract

Insights

Oncogramme accurately predicts patient response to Herceptin, a breast cancer drug targeting Human Epidermal Growth Factor Receptor-2 (HER2). This ex vivo method correlates cell sensitivity with HER2 expression, aiding personalized chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Herceptin is a targeted therapy monoclonal antibody for HER2-expressing breast cancer.
  • Oncogramme is an ex vivo method to predict anticancer drug activity and personalize treatment.
  • Clinical validation of Oncogramme requires correlation with HER2 expression in breast cancer cells.

Purpose of the Study:

  • To correlate breast cancer cell responses to Herceptin using Oncogramme with HER2 expression levels.
  • To validate Oncogramme as a predictive tool for individualized chemotherapy.

Main Methods:

  • Breast tumor fragments were dissociated into cells and cultured.
  • Cells were treated with Herceptin, and cytotoxicity was assessed via cell death analysis.
  • Pathologists determined tumor HER2 status for comparison with cell responses.

Main Results:

  • Oncogramme-observed cell responses to Herceptin correlated with HER2 expression levels.
  • A direct relationship was found between increasing Herceptin doses and cell response.

Conclusions:

  • The Oncogramme method reliably predicts patient cell sensitivity to anticancer drugs like Herceptin.
  • This correlation supports Oncogramme's potential for personalized breast cancer treatment strategies.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.